GlassScriptPhysician profile
Mary Transue
NPI 1538984109
$1,602.91
in general payments reported to CMS, 2019-2025
15 companies · $1,603 in 2025
The $1,603 reported for 2025 was more than what 90% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,603.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,602.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $283.23 | 2025 | Tremfya, Simponi, Stelara |
| Ucb, INC. | $249.64 | 2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $245.74 | 2025 | |
| Abbvie INC. | $211.03 | 2025 | |
| Organon LLC | $160.69 | 2025 | Vtama |
| Pfizer INC. | $66.29 | 2025 | |
| Arcutis Biotherapeutics, INC. | $64.93 | 2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $60.45 | 2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $55.88 | 2025 | Ebglyss, Taltz |
| Genzyme Corporation | $47.97 | 2025 | |
| Incyte Corporation | $44.16 | 2025 | Opzelura |
| Galderma Laboratories, L.P. | $38.42 | 2025 | Nemluvio |
| Sun Pharmaceutical Industries INC. | $34.04 | 2025 | |
| Botanix Sb INC | $25.38 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $15.06 | 2025 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Transue listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.